US Biotech in Europe
US Biotech in Europe How HTA Bodies Can Boost Your US Payer Negotiations The rare disease landscape presents unique challenges and opportunities for pharmaceutical and biotech companies. While the US market offers a large patient population and potential for high drug prices, navigating the complex regulatory and payer landscape can be daunting. For US-based companies […]
Bringing Cell Therapies to Rare Disease Patients in Europe
Bringing Cell Therapies to Rare Disease Patients in Europe Rare diseases are defined by sheer numbers of new patients per population. This definition is not helpful for the affected patient and his/her family. These conditions often lack effective treatment options due to their low prevalence. In addition, there are challenges in developing traditional pharmaceuticals for […]
The Geopolitics of Hope
The Geopolitics of Hope A Flourishing Market, Yet Millions in Europe Lack Access to Rare Disease Treatments Did you know that over 30 million people in Europe live with a rare disease, often lacking access to effective treatments due to the complexities of market entry? This challenge highlights a missed opportunity. According to 2022 global […]
